Advertisement

Chromatographia

, Volume 81, Issue 5, pp 777–783 | Cite as

HPLC–UV Chromatographic Methods for Detection and Quantification of Undeclared Withdrawn Synthetic Medications in Counterfeit Herbal Medicines with Confirmation by HPLC–PDA and Mass Spectrometry

  • A. Hemdan
  • Shereen M. Tawakol
Original

Abstract

Adulteration of herbal medicinal products with synthetic pharmaceuticals remains a serious problem. The purpose of this study is to develop a procedure for determination of some common synthetic adulterants in some herbal remedies available on the market, utilizing a reversed-phase high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection. Herbal medicines for weight loss and another for erectile dysfunction were tested for presence of conceivable adulterants. The weight loss products were discovered to be defiled with the effectively withdrawn drug sibutramine (SIB) and with phenolphthalein (PPH), which has been demonstrated to cause tumors. On the other hand, sildenafil (SLD), a medication contraindicated for patients with heart diseases (sometimes causing serious side-effects with respect to blood pressure), was found in the herbal product for erectile dysfunction. The mobile phase for quantification of sibutramine and phenolphthalein was acetonitrile–potassium hydrogen phosphate buffer (pH 3) adjusted using o-phosphoric acid (40/60 v/v) with detection at 223 nm. Meanwhile, the mobile phase for sildenafil was acetonitrile–potassium hydrogen phosphate buffer (pH 3.2) adjusted using o-phosphoric acid (50/50 v/v) with detection at 230 nm. Presence of the adulterants was confirmed using LC–photodiode array (PDA) and mass spectrometry.

Graphical Abstract

Keywords

LC–PDA MS/MS Herbal medicines Adulteration Sibutramine Sildenafil 

Notes

Funding

The authors received no funding to carry out this study.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Human animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

10337_2018_3502_MOESM1_ESM.docx (207 kb)
Supplementary material 1 (DOCX 207 kb)
10337_2018_3502_MOESM2_ESM.docx (251 kb)
Supplementary material 2 (DOCX 250 kb)
10337_2018_3502_MOESM3_ESM.docx (193 kb)
Supplementary material 3 (DOCX 192 kb)
10337_2018_3502_MOESM4_ESM.docx (209 kb)
Supplementary material 4 (DOCX 209 kb)
10337_2018_3502_MOESM5_ESM.docx (214 kb)
Supplementary material 5 (DOCX 214 kb)
10337_2018_3502_MOESM6_ESM.docx (194 kb)
Supplementary material 6 (DOCX 193 kb)

References

  1. 1.
    Guidelines for the Appropriate Use of Herbal Medicines (1998) WHO Regional Publications, WHO Regional Office for The Western Pacific, ManilaGoogle Scholar
  2. 2.
    WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems, WHO, Geneva, 2004Google Scholar
  3. 3.
    Kasilo OMJ, Trapsida JM (2011) Afr Health Mon (Special Issue) 14:25–31Google Scholar
  4. 4.
    Ernst E, Pittler MH (2002) Complement Altern Med 86:149–161Google Scholar
  5. 5.
    Ernst E (2000) In: Dukes MNG, Aronson JK (eds) Meyler’s side effects of drugs, 14th edn. Elsevier Science, Amsterdam, pp 1649–1681Google Scholar
  6. 6.
    Johns A (2008) Nature, 451Google Scholar
  7. 7.
    Mills S, Bone K (2005) The essential guide to herbal safety. Elsevier, Maryland HeightsGoogle Scholar
  8. 8.
    Balayssac S, Trefi S, Gilard V et al (2009) J Pharm Biomed Anal 50:602–612CrossRefGoogle Scholar
  9. 9.
    Kesting JR, Huang J, Sørensen D (2010) J Pharm Biomed Anal 51:705–711CrossRefGoogle Scholar
  10. 10.
    Singh S, Prasad B, Savaliya AA et al (2009) Trends Anal Chem 28:13–28CrossRefGoogle Scholar
  11. 11.
    de Carvalho LM, Martini M, Moreira APL, de Lima APS, Correia D, Falcao T, Garcia SC, de Bairros AV, do Nascimento PC, Bohrer D (2010) Forensic Sci Int 204:6–12CrossRefGoogle Scholar
  12. 12.
    Yu Z, Wei Q, Fan Q, Wan C (2010) J Liq Chromatogr 33:452–461CrossRefGoogle Scholar
  13. 13.
    James WPT et al (2010) N Engl J Med 363:905–917CrossRefGoogle Scholar
  14. 14.
    Jung J, Hermanns-Clausen M, Weinmann W (2006) Forensic Sci Int 161:221–222CrossRefGoogle Scholar
  15. 15.
    Luque CA, Rey JA (2002) Eur J Pharmacol 440:119–128CrossRefGoogle Scholar
  16. 16.
    Walsh KM, Leen E, Lean MEJ (1999) Int J Obes 23:1009–1015CrossRefGoogle Scholar
  17. 17.
    Tang MHY (2011) Br J Clin Pharmacol 71:250–253CrossRefGoogle Scholar
  18. 18.
    Mondaini N et al (2003) Int J Impot Res 15:225–228.  https://doi.org/10.1038/sj.ijir.3901005 CrossRefGoogle Scholar
  19. 19.
    Indications and Clinical Use, Product Monograph of VIAGRA (sildenafil citrate), Revised in 26 August 2013Google Scholar
  20. 20.
    Blachut D, Siwinska-Ziolkowska A, Szukalski B, Wojtassiewicz K, Czarnocki Z, Kobylecka A, Bykas-Strekowska M (2007) Prob Forensic Sci 70:225–235Google Scholar
  21. 21.
    Stypulkowska K, Blazewicz A, Maurin J, Sarna K (2001) J Pharm Biomed Anal 56:969–975CrossRefGoogle Scholar
  22. 22.
    Wei M, Tao P, Ming-Da Z, Xiao-Juan L, Qiang M, Dong-Dong C, Li L, Wei G, Ying-Zhang T (2009) Chin J Anal Chem 37:1583–1589Google Scholar
  23. 23.
    Wang J, Chen B, Yao S (2008) Food Addit Contam 25:822–830CrossRefGoogle Scholar
  24. 24.
    Shi Y, Sun C, Gao B, Sun A (2011) J Chromatogr A 1218:7655–7662CrossRefGoogle Scholar
  25. 25.
    Roh SH, Kang YP, Park S, Huh Y, Lee J, Park JH, Kim D, Kwon SW (2011) Food Addit Contam 11:1475–1482CrossRefGoogle Scholar
  26. 26.
    Mu-changseng T, Hueilun J (2002) J Food Drug Anal 10(2):112–119Google Scholar
  27. 27.
    Gratz SR, Flurer CL, Wolnik KA (2004) J Pharm Biomed Anal 36:525–533CrossRefGoogle Scholar
  28. 28.
    Liang Q, Qu J, Luo G, Wang Y (2005) J Pharm Biomed Anal 2005, online at www.sciencedirect.com
  29. 29.
    Vaysse J, Balayssac S, Gilard V, Desoubdzanne D, Malet-Martino M, Martino R (2010) Food Addit Contam 27:903–916CrossRefGoogle Scholar
  30. 30.
    Stypulkowska K, Blazewicz A, Maurin J, Sarna K, Fijalek Z (2011) J Pharm Biomed Anal 56:969–975CrossRefGoogle Scholar
  31. 31.
    Kanan S, Abu-Yousef IA, Gunasekar C, Abdo N, Narasimhan S (2009) Eur J Sci Res 34:348–357Google Scholar
  32. 32.
    Kamil M, Naji MA (2011) VIVECHAN-IJR. 2Google Scholar
  33. 33.
    Zou P, Oczxch SSY, Kiang K-H, Low M-Y, Bloodworth BC (2007) Rapid Commun Mass Spectrom 21:614–618CrossRefGoogle Scholar
  34. 34.
    Nanita SC, Pentz AM, Bramble FQ (2009) Anal Chem 81:3134–3142CrossRefGoogle Scholar
  35. 35.
    [Dietary supplements: What you need to know. Office of Dietary Supplements. http://ods.od.nih.gov/pubs/DS_WhatYouNeedToKnow.pdf. Accessed 15 Sept 2014. Tips for dietary supplement users. U.S Food and Drug Administration]
  36. 36.
  37. 37.
    ICH (2005) Validation of analytical procedures: text and methodology Q2 (R1). International Conference on Harmonization; 2005; GenevaGoogle Scholar
  38. 38.
    Segall A, Collado E, Ricci R, Pizzorno M, Altiokka G (2003) J Liq Chromatogr Relat Technol 26:977–986CrossRefGoogle Scholar
  39. 39.
    Izquierdohornillos R (1993) Microchem J 48:356–364CrossRefGoogle Scholar
  40. 40.
    Ergun B, Saracoglu A, Ilgin S, Atkosar Z, Kircali K, Altiokka G (2005) J Liq Chromatogr Relat Technol 28:1539–1548CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutical Analytical Chemistry, Faculty of PharmacyAhram Canadian University6th of OctoberEgypt
  2. 2.Department of Pharmaceutical Analytical Chemistry, Faculty of PharmacyHelwan UniversityHelwanEgypt

Personalised recommendations